Coffey LL

No ORCID on file · 4 papers in corpus · active 2020-2021
2021
·doi:10.2139/ssrn.3886997

Anti-viral monoclonal antibody (mAb) treatments may provide immediate but short-term immunity from COVID-19 in high-risk populations such as aged and diabetic individuals, however, data on their efficacy in these populations is limited. We …

2021
Cell reports ·doi:10.1016/j.celrep.2021.109942

Anti-viral monoclonal antibody (mAb) treatments may provide immediate but short-term immunity from coronavirus disease 2019 (COVID-19) in high-risk populations, such as people with diabetes and the elderly; however, data on their efficacy i…

2021
Journal of virology ·doi:10.1128/jvi.00403-21

To understand susceptibility of wild California sea lions and Northern elephant seals to influenza A virus (IAV), we developed an ex vivo respiratory explant model and used it to compare infection kinetics for multiple IAV subtypes. We firs…

2020
·doi:10.1101/2020.10.15.342055

To understand susceptibility of wild California sea lions and Northern elephant seals to influenza A virus (IAV), we developed an ex vivo respiratory explant model and used it to compare infection kinetics for multiple IAV subtypes. We fir…